Radafaxine HCl

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 529912

CAS#: 106083-71-0 (HCl).

Description: Radafaxine, also known BW-306U and GW-353162, is a dopamine reuptake inhibitor potentially for the reatment of restless legs syndrome and major depression.

Price and Availability


USD 250

USD 450

USD 850

Radafaxine HCl, purity > 98%, is in stock. Current shipping out time is about 2 weeks after order is received. CoA, QC data and MSDS documents are available in one week after order is received.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 529912
Name: Radafaxine HCl
CAS#: 106083-71-0 (HCl).
Chemical Formula: C13H19Cl2NO2
Exact Mass:
Molecular Weight: 292.2
Elemental Analysis: C, 53.44; H, 6.55; Cl, 24.26; N, 4.79; O, 10.95

Related CAS #: 192374-14-4 (free base)   106083-71-0 (HCl)    

Synonym: BW-306U; GW-353162A; GW-353162; BW306U; GW353162A; GW353162; BW 306U; GW 353162A; GW353162

IUPAC/Chemical Name: (2S,3S)-2-(3-chlorophenyl)-3,5,5-trimethylmorpholin-2-ol hydrochloride


InChi Code: InChI=1S/C13H18ClNO2.ClH/c1-9-13(16,17-8-12(2,3)15-9)10-5-4-6-11(14)7-10;/h4-7,9,15-16H,8H2,1-3H3;1H/t9-,13+;/m0./s1

SMILES Code: O[C@]1(C2=CC=CC(Cl)=C2)[C@H](C)NC(C)(C)CO1.[H]Cl

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:


1: Volkow ND, Wang GJ, Fowler JS, Learned-Coughlin S, Yang J, Logan J, Schlyer D, Gatley JS, Wong C, Zhu W, Pappas N, Schueller M, Jayne M, Carter P, Warner D, Ding YS, Shea C, Xu Y. The slow and long-lasting blockade of dopamine transporters in human brain induced by the new antidepressant drug radafaxine predict poor reinforcing effects. Biol Psychiatry. 2005 Mar 15;57(6):640-6. PubMed PMID: 15780851.

2: Molnari JC, Hassan HE, Myers AL. Effects of sertraline on the pharmacokinetics of bupropion and its major metabolite, hydroxybupropion, in mice. Eur J Drug Metab Pharmacokinet. 2012 Mar;37(1):57-63. doi: 10.1007/s13318-011-0065-6. PubMed PMID: 21928040.

3: Livshits Z, Feng Q, Chowdhury F, Amdo TD, Nelson LS, Hoffman RS. Life-threatening bupropion ingestion: is there a role for intravenous fat emulsion? Basic Clin Pharmacol Toxicol. 2011 Nov;109(5):418-22. doi: 10.1111/j.1742-7843.2011.00750.x. PubMed PMID: 21726409.

4: Carroll FI, Muresan AZ, Blough BE, Navarro HA, Mascarella SW, Eaton JB, Huang X, Damaj MI, Lukas RJ. Synthesis of 2-(substituted phenyl)-3,5,5-trimethylmorpholine analogues and their effects on monoamine uptake, nicotinic acetylcholine receptor function, and behavioral effects of nicotine. J Med Chem. 2011 Mar 10;54(5):1441-8. doi: 10.1021/jm1014555. PubMed PMID: 21319801; PubMed Central PMCID: PMC3048909.

5: Parekh JM, Sutariya DK, Vaghela RN, Sanyal M, Yadav M, Shrivastav PS. Sensitive, selective and rapid determination of bupropion and its major active metabolite, hydroxybupropion, in human plasma by LC-MS/MS: application to a bioequivalence study in healthy Indian subjects. Biomed Chromatogr. 2012 Mar;26(3):314-26. doi: 10.1002/bmc.1660. PubMed PMID: 21656534.

6: Lei HP, Yu XY, Xie HT, Li HH, Fan L, Dai LL, Chen Y, Zhou HH. Effect of St. John's wort supplementation on the pharmacokinetics of bupropion in healthy male Chinese volunteers. Xenobiotica. 2010 Apr;40(4):275-81. doi: 10.3109/00498250903509383. PubMed PMID: 20102294.

7: Hu L, Wang Z, Xu R, Ma J, Wang X, Zhang X. Determination of bupropion and its main metabolite in rat plasma by LC-MS and its application to pharmacokinetics. Pharmazie. 2011 Dec;66(12):924-8. PubMed PMID: 22312695.

8: Hansard MJ, Jackson MJ, Smith LA, Rose S, Jenner P. A major metabolite of bupropion reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets. Behav Pharmacol. 2011 Jun;22(3):269-74. doi: 10.1097/FBP.0b013e328345ca37. PubMed PMID: 21522056.

9: Yeniceli D, Sener E, Korkmaz OT, Doğrukol-Ak D, Tuncel N. A simple and sensitive LC-ESI-MS (ion trap) method for the determination of bupropion and its major metabolite, hydroxybupropion in rat plasma and brain microdialysates. Talanta. 2011 Mar 15;84(1):19-26. doi: 10.1016/j.talanta.2010.11.063. PubMed PMID: 21315892.

10: Chung JY, Cho JY, Lim HS, Kim JR, Yu KS, Lim KS, Shin SG, Jang IJ. Effects of pregnane X receptor (NR1I2) and CYP2B6 genetic polymorphisms on the induction of bupropion hydroxylation by rifampin. Drug Metab Dispos. 2011 Jan;39(1):92-7. doi: 10.1124/dmd.110.035246. PubMed PMID: 20876786.

11: Fan L, Wang JC, Jiang F, Tan ZR, Chen Y, Li Q, Zhang W, Wang G, Lei HP, Hu DL, Wang D, Zhou HH. Induction of cytochrome P450 2B6 activity by the herbal medicine baicalin as measured by bupropion hydroxylation. Eur J Clin Pharmacol. 2009 Apr;65(4):403-9. doi: 10.1007/s00228-008-0594-3. PubMed PMID: 19066872.

12: Chen Y, Liu HF, Liu L, Nguyen K, Jones EB, Fretland AJ. The in vitro metabolism of bupropion revisited: concentration dependent involvement of cytochrome P450 2C19. Xenobiotica. 2010 Aug;40(8):536-46. doi: 10.3109/00498254.2010.492880. PubMed PMID: 20528624.

13: Kim H, Bae SK, Park SJ, Shim EJ, Kim HS, Shon JH, Liu KH, Shin JG. Effects of woohwangcheongsimwon suspension on the pharmacokinetics of bupropion and its active metabolite, 4-hydroxybupropion, in healthy subjects. Br J Clin Pharmacol. 2010 Jul;70(1):126-31. doi: 10.1111/j.1365-2125.2010.03661.x. PubMed PMID: 20642555; PubMed Central PMCID: PMC2909815.

14: Denooz R, Mercerolle M, Lachâtre G, Charlier C. Ultra-performance liquid chromatography- tandem mass spectrometry method for the determination of bupropion and its main metabolites in human whole blood. J Anal Toxicol. 2010 Jun;34(5):280-6. PubMed PMID: 20529462.

15: Lukas RJ, Muresan AZ, Damaj MI, Blough BE, Huang X, Navarro HA, Mascarella SW, Eaton JB, Marxer-Miller SK, Carroll FI. Synthesis and characterization of in vitro and in vivo profiles of hydroxybupropion analogues: aids to smoking cessation. J Med Chem. 2010 Jun 24;53(12):4731-48. doi: 10.1021/jm1003232. PubMed PMID: 20509659; PubMed Central PMCID: PMC2895766.

16: Joy MS, Frye RF, Stubbert K, Brouwer KR, Falk RJ, Kharasch ED. Use of enantiomeric bupropion and hydroxybupropion to assess CYP2B6 activity in glomerular kidney diseases. J Clin Pharmacol. 2010 Jun;50(6):714-20. doi: 10.1177/0091270009353031. PubMed PMID: 20103693; PubMed Central PMCID: PMC3614080.

17: Kharasch ED, Mitchell D, Coles R, Blanco R. Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir. Antimicrob Agents Chemother. 2008 May;52(5):1663-9. doi: 10.1128/AAC.01600-07. PubMed PMID: 18285471; PubMed Central PMCID: PMC2346649.

18: Lei HP, Ji W, Lin J, Chen H, Tan ZR, Hu DL, Liu LJ, Zhou HH. Effects of Ginkgo biloba extract on the pharmacokinetics of bupropion in healthy volunteers. Br J Clin Pharmacol. 2009 Aug;68(2):201-6. doi: 10.1111/j.1365-2125.2009.03442.x. PubMed PMID: 19694739; PubMed Central PMCID: PMC2767283.

19: Kiptoo PK, Paudel KS, Hammell DC, Pinninti RR, Chen J, Crooks PA, Stinchcomb AL. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J Pharm Sci. 2009 Feb;98(2):583-94. doi: 10.1002/jps.21463. PubMed PMID: 18623203; PubMed Central PMCID: PMC2612091.

20: Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR. Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):513-9. doi: 10.1097/QAI.0b013e318183a425. PubMed PMID: 18989234.